The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Semaglutide , a dual GIP/GLP-1 receptor activator , alongside Another Agent, a triple GIP/GLP-1/GCG receptor activator, are demonstrating impressive results in correcting obesity and glucose control. Furthermore, the inclusion of NMN, a critical coe